Unicycive Therapeutics, Inc. financial data

Symbol
UNCY on Nasdaq
Industry
Pharmaceutical Preparations
Location
4300 El Camino Real, Suite 210, Los Altos, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 167 % +10.7%
Quick Ratio 25.1 %
Debt-to-equity -196 % -43.1%
Return On Equity 234 % -39.5%
Return On Assets -71.1 % +61.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 94.4M shares +172%
Common Stock, Shares, Outstanding 43.6M shares +186%
Entity Public Float 19.5M USD +56.2%
Common Stock, Value, Issued 43K USD +187%
Weighted Average Number of Shares Outstanding, Basic 37.9M shares +149%
Weighted Average Number of Shares Outstanding, Diluted 94.1M shares +517%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 675K USD
Research and Development Expense 19.3M USD +38.4%
General and Administrative Expense 9.57M USD +35%
Operating Income (Loss) -28.9M USD -48.7%
Nonoperating Income (Expense) 17.3M USD +3465%
Net Income (Loss) Attributable to Parent -23.2M USD +20.7%
Earnings Per Share, Basic -0.55 USD/shares +72.2%
Earnings Per Share, Diluted -0.78 USD/shares +60.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 14.3M USD +105%
Inventory, Net 3.11M USD +56.6%
Assets, Current 44.1M USD +101%
Property, Plant and Equipment, Net 43K USD +43.3%
Operating Lease, Right-of-Use Asset 604K USD -34.6%
Assets 44.7M USD +95.3%
Accounts Payable, Current 1.47M USD +193%
Accrued Liabilities, Current 3.12M USD +84.8%
Liabilities, Current 13.1M USD -15.1%
Operating Lease, Liability, Noncurrent 274K USD -56.8%
Liabilities 13.4M USD -16.8%
Retained Earnings (Accumulated Deficit) -75.6M USD -44.3%
Stockholders' Equity Attributable to Parent -14.8M USD +23.4%
Liabilities and Equity 44.7M USD +95.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.46M USD -64.7%
Net Cash Provided by (Used in) Financing Activities 45.7M USD +64.4%
Net Cash Provided by (Used in) Investing Activities -6K USD
Common Stock, Shares Authorized 400M shares +100%
Common Stock, Shares, Issued 43.6M shares +186%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 23.9M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 41.8M USD +122%
Interest Paid, Excluding Capitalized Interest, Operating Activities 5M USD
Deferred Tax Assets, Valuation Allowance 11.2M USD +50.3%
Deferred Tax Assets, Gross 11.3M USD +51.8%
Operating Lease, Liability 634K USD
Depreciation 9K USD +350%
Payments to Acquire Property, Plant, and Equipment 6K USD
Lessee, Operating Lease, Liability, to be Paid 693K USD
Property, Plant and Equipment, Gross 68K USD +61.9%
Operating Lease, Liability, Current 360K USD +18.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 72K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 424K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 59K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 72K USD
Deferred Tax Assets, Operating Loss Carryforwards 5.98M USD +43.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 9.9M shares +32708%
Unrecognized Tax Benefits 1.03M USD +48.8%
Additional Paid in Capital 60.8M USD +84%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 161K USD +403%
Share-based Payment Arrangement, Expense 641K USD +345%
Interest Expense 90K USD +66.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%